In Honor of Men’s Health Month, Teleflex Announces Virtual Community Health Talk for Men with Benign Prostatic Hyperplasia
June 08 2020 - 5:00PM
Teleflex Incorporated (NYSE: TFX) today announced that the company
will host a free community health talk to discuss the symptoms,
diagnosis and treatment options for enlarged prostate, also known
as Benign Prostatic Hyperplasia (BPH). Dr. Wayne Kuang* will lead
the webinar which can be viewed live on Wednesday, June 17 at 8:00
a.m. PDT and again at 4:30 p.m. PDT. Men and / or their partners
from anywhere in the U.S. can attend the event.
BPH is a non-cancerous enlargement of the prostate that occurs
as men age. This common condition is marked by bothersome urinary
symptoms that can cause loss of productivity, depression,
interrupted sleep and decreased quality of life.1 If left
untreated, the condition can worsen over time and cause permanent
bladder damage.2
“We are excited to offer our first ever virtual community health
talk – a result of our efforts to stay connected with our patient
community during the current pandemic,” said Dave Amerson,
president of Teleflex Interventional Urology business unit.
“Maintaining health is top of mind for many of us as we continue to
navigate life in the midst of a pandemic. Our aim is to share
information about BPH to a broad audience so that men who may be
suffering from symptoms have accurate and reliable information they
need to make informed decisions for their health.”
“As providers, we are dedicated to empowering our patients to
get the information they need to make informed decisions about
their health during this unprecedented time,” said Dr. Wayne Kuang,
MD For Men, Albuquerque, NM. “Our goal for this timely webinar
during Men’s Health Month is to provide attendees with a better
understanding of how to address the challenges of an enlarged
prostate – a condition that affects more than 40 million men in the
U.S. alone3,4– and provide information about treatment solutions,
such as the UroLift® System, for those experiencing BPH
symptoms.”
Register to participate in this informative webinar by following
this link: www.UroLift.com/seminar.
About the
UroLift® SystemThe FDA-cleared UroLift
System is a proven, minimally invasive technology for treating
lower urinary tract symptoms due to benign prostatic hyperplasia
(BPH). The UroLift permanent implants, delivered during a minimally
invasive transurethral outpatient procedure, relieve prostate
obstruction and open the urethra directly without cutting, heating,
or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and
durable symptomatic and urinary flow rate improvement without
compromising sexual function.**3,4 Patients also experienced
significant improvement in quality of life. Over 175,000 men have
been treated with the UroLift System worldwide.*** Most common
adverse events reported include hematuria, dysuria, micturition
urgency, pelvic pain, and urge incontinence. Most symptoms were
mild to moderate in severity and resolved within two to four weeks
after the procedure. The Prostatic Urethral Lift procedure (using
the UroLift System) is recommended for the treatment of BPH in both
the American Urological Association and European Association of
Urology clinical guidelines. The UroLift System is available in
many markets worldwide. Learn more at www.UroLift.com.
About Teleflex Interventional UrologyThe
Teleflex Interventional Urology Business Unit is dedicated to
developing innovative, minimally invasive and clinically effective
devices that address unmet needs in the field of urology. Our focus
is on improving the standard of care for patients with BPH using
the UroLift System, a minimally invasive permanent implant system
that treats symptoms while preserving sexual function.**4,5 Learn
more at www.NeoTract.com.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular and interventional access,
surgical, anesthesia, cardiac care, urology, emergency medicine and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a
common sense of purpose.
Contacts:For Teleflex Incorporated:Jake
Elguicze, 610.948.2836Treasurer and Vice President, Investor
Relations
Media:Nicole Osmer, 650.454.0504nicole@healthandcommerce.com
*Dr. Kuang is a paid consultant of NeoTract/Teleflex**No
instances of new, sustained erectile or ejaculatory
dysfunction***Management estimate based on product sales and
average units per procedure.1. Speakman et al. 2014 BJUI
International2. Tubaro et al. 2003 Drugs Aging3. Roehrborn, J
Urology 2013 LIFT Study4. Shore, Can J Urol 2014 Local Study5.
Speakman et al. 2014 BJUI International
MAC01500-01 Rev A
Teleflex (NYSE:TFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Sep 2023 to Sep 2024